Our vaccine pipeline

Our vaccine pipeline​

At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solutions.​

​

Our clinical portfolio comprises highly differentiated vaccine candidates designed to deliver preventive solutions for infectious diseases with high unmet medical needs.​

Our goal is to develop first‑ or best‑in‑class vaccine candidates and bring them toward future commercialization—either independently or with partners.

Clinical candidates​

• VLA15 is a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, under development in collaboration with Pfizer, and it is the only vaccine candidate against Lyme disease currently undergoing late-stage clinical trials. Pfizer and Valneva are currently executing the Phase 3 field efficacy study for VLA15 called VALOR (Vaccine Against Lyme for Outdoor Recreationists). Topline Phase 3 results are expected in the first half of 2026. Vaccinations were completed in July 2025 and participants were monitored for the occurence of Lyme disease cases until the end of 2025. VLA15 targets the six most prevalent serotypes of Borrelia in the Northern Hemisphere. In the United States approximately 476,000 people are diagnosed with Lyme disease each year and in Europe at least a further 132,000 cases occur annually.
  ​
• VLA1553 is a Phase 3/4 single-dose, live-attenuated vaccine candidate against chikungunya, marketed under the brand name IXCHIQ. It is currently approved for use in individuals 12 years of age and older in Europe and Canada and in individuals 18 years to 59 years of age in the UK and Brazil. IXCHIQ received approval in the United States in November 2023; however, in January 2026, the Company voluntarily withdrew both the Biologics License Application (BLA) and the Investigational New Drug (IND) application.​
  ​
• VLA1601 is a Phase 1 vaccine candidate targeting the Zika virus (ZIKV), a mosquito-borne viral disease whose transmission has been reported in 89 countries and territories and persists in several countries in the Americas and other endemic regions. There are no preventive vaccines or effective treatments available. As such, Zika remains a public health threat and is included in the FDA’s Tropical Disease Priority Review Voucher Program. We reported positive Phase 1 results in November 2025 and will only consider further potential development steps for VLA1601 if concrete private and public funding opportunities materialize.​

​

Pre-clinical candidates​

• VLA2112, our EBV vaccine candidate, is based on adjuvanted, subunit viral glycoproteins to elicit high titers of EBV-neutralizing antibodies. ​The selection of antigens that best neutralize infection of both epithelial cells and B cells was completed in 2023 and confirmatory preclinical research is ongoing.
  ​

In addition to VLA2112, we are working on several candidates against enteric diseases.